Effects of Ketamine on Postoperative Pain After Remifentanil-Based Anesthesia for Major and Minor Surgery in Adults: A Systematic Review and Meta-Analysis by García Henares, Juan et al.
SYSTEMATIC REVIEW
published: 17 August 2018
doi: 10.3389/fphar.2018.00921
Frontiers in Pharmacology | www.frontiersin.org 1 August 2018 | Volume 9 | Article 921
Edited by:
Milica S. Prostran,
University of Belgrade, Serbia
Reviewed by:
Robert L. Barkin,
Rush University Medical Center,
United States
Dragana Srebro,





This article was submitted to
Neuropharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 17 April 2018
Accepted: 26 July 2018
Published: 17 August 2018
Citation:
García-Henares JF, Moral-Munoz JA,
Salazar A and Del Pozo E (2018)
Effects of Ketamine on Postoperative
Pain After Remifentanil-Based
Anesthesia for Major and Minor




Effects of Ketamine on Postoperative
Pain After Remifentanil-Based
Anesthesia for Major and Minor
Surgery in Adults: A Systematic
Review and Meta-Analysis
Juan F. García-Henares 1, Jose A. Moral-Munoz 2,3*, Alejandro Salazar 3,4,5 and
Esperanza Del Pozo 6
1Hospital Marina Salud, Dénia, Alicante, Spain, 2Department of Nursing and Physiotherapy, University of Cádiz, Cádiz, Spain,
3 Institute of Research and Innovation in Biomedical Sciences of the Province of Cadiz (INiBICA), University of Cádiz, Cádiz,
Spain, 4 Preventive Medicine and Public Health Area, University of Cádiz, Cádiz, Spain, 5 The Observatory of Pain (External
Chair of Pain), University of Cádiz, Cádiz, Spain, 6Department of Pharmacology, Faculty of Medicine, Institute of
Neurosciences, Biomedical Research Institute Granada, University of Granada, Granada, Spain
Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has been postulated
as an adjuvant analgesic for preventing remifentanil-induced hyperalgesia after surgery.
This systematic review and meta-analysis aims to assess the effectiveness of ketamine
[racemic mixture and S-(+)-ketamine] in reducing morphine consumption and pain
intensity scores after remifentanil-based general anesthesia. We performed a literature
search of the PubMed, Web of Science, Scopus, Cochrane, and EMBASE databases
in June 2017 and selected randomized controlled trials using predefined inclusion and
exclusion criteria. To minimize confounding and heterogeneity, studies of NMDA receptor
antagonists other than ketamine were excluded and the selected studies were grouped
into those assessing minor or major surgery. Methodological quality was evaluated
with the PEDro and JADA scales. The data were extracted and meta-analyses were
performed where possible. Twelve RCTs involving 156 adults who underwent minor
surgery and 413 adults who underwent major surgery were included in themeta-analysis.
When used as an adjuvant to morphine, ketamine reduced postoperative morphine
consumption in the first 24 h and postoperative pain intensity in the first 2 h in the minor
and major surgery groups. It was also associated with significantly reduced pain intensity
in the first 24 h in the minor surgery group. Time to the first rescue analgesia was longer in
patients who received ketamine and underwent major surgery. No significant differences
in the incidence of ketamine-related adverse effects were observed among patients in
the intervention group and controls. This systematic review and meta-analysis show that
low-dose (≤0.5 mg/kg for iv bolus or ≤5 µg/kg/min for iv perfusion) of ketamine reduces
postoperative morphine consumption and pain intensity without increasing the incidence
of adverse effects.
Keywords: remifentanil, ketamine, minor surgery, mayor surgery, NMDA antagonist, meta-analysis
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INTRODUCTION
Management of chronic postsurgical pain remains a challenge
for anesthesiologists and surgeons. Approximately 240 million
surgical procedures are performed worldwide each year, and
an estimated 12% of patients still report moderate to intense
pain 1 year after surgery (Fletcher et al., 2015). Inadequately
treated pain could be considered an adverse postoperative effect,
as it can lead to longer hospital stays, higher costs, and lower
patient satisfaction (Shipton, 2014). Acute postoperative pain is
also a risk factor for the development of chronic postsurgical
pain (Perkins and Kehlet, 2000), and the relationship appears
to be directly proportional, with more intense or longer-lasting
pain linked to a higher incidence of chronic pain (Mion and
Villevieille, 2013; Pozek et al., 2016; Reddi, 2016).
Remifentanil is a widely used general anesthesia thanks to
its pharmacodynamic and pharmacokinetic properties (Kim
et al., 2015). Its potency as an opioid agonist combined with a
short elimination half-life without accumulating with prolonged
infusion allows anesthesiologists to maintain hemodynamic
stability during surgery without risk of delayed awakening.
Intraoperative remifentanil infusion has, however, been
associated with opioid-induced hyperalgesia (Joly et al., 2005;
Fletcher and Martinez, 2014).
The N-methyl-D-aspartate (NMDA) receptor is believed to
play an important role in the pathophysiology of opioid-induced
hyperalgesia (Mao et al., 1995; Mayer et al., 1999; Williams
et al., 2001; Ossipov et al., 2005; Angst and Clark, 2006;
Mao, 2006). Ketamine is a non-competitive NMDA receptor
antagonist (Mion and Villevieille, 2013) authorized by the U.S.
Food and Drug Administration as an anesthetic drug and it is
used in multimodal analgesia regimens to improve postoperative
pain control (Chou et al., 2016). The classic anesthetic effect
of ketamine is described as a dose-dependent central nervous
system (CNS) depression that leads to a dissociative state
characterized by profound analgesia and amnesia but not
necessarily loss of consciousness (Kohrs and Durieux, 1998).
The use of low subanesthetic doses of ketamine (no more than
1 mg/kg iv bolus or 20 µg/kg/min continuous infusion) as an
adjuvant to morphine in postoperative multimodal analgesia
regimens (Schmid et al., 1999) is supported by several lines
of evidence: (i) the mechanism of action of ketamine and
the importance of the NMDA neurotransmission system in
nociceptive processing (Bell et al., 2015); (ii) evidence that
ketamine potentiates the analgesic effects of opioids, suggesting
that it could reduce acute postoperative pain and minimize
opioid consumption (Carstensen and Möller, 2010; Song et al.,
2013); and (iii) the low toxicity of subanesthetic doses of
ketamine (Michelet et al., 2007). In addition, recent studies
have attributed additional antihyperalgesic, neuroprotective,
antidepressant, and anti-inflammatory effects to ketamine based
on its interaction with multiple other receptors, such as AMPA,
kainate, gamma-aminobutyric acid (GABA), opiate, muscarinic,
as well as voltage-gated sodium and hyperpolarization-activated
cyclic nucleotide-gated channels (Zanos et al., 2018). The isomer
S(+)-ketamine (also named Esketamine) is reported to be twice
as potent as the racemic mixture as an anesthetic (Zanos et al.,
2018). Despite these seemingly “ideal” qualities of ketamine,
however, contradictory results have been reported for the efficacy
of ketamine in multimodal perioperative analgesia regimens.
We wondered if there was clinical evidence supporting the
use of perioperative ketamine to improve postoperative pain
after remifentanil-based anesthesia in adults. To our knowledge,
only two meta-analyses, each analyzing 14 randomized controls
trials (RCTs), have been conducted (Liu et al., 2012; Wu
et al., 2015) and they reported conflicting findings One of the
analyses found no significant evidence that NMDA antagonists
prevented remifentanil-associated hyperalgesia (Wu et al., 2015),
while the other one showed that ketamine significantly reduced
postoperative pain and cumulative morphine consumption (Wu
et al., 2015). This benefit was also found in a meta-analysis of the
addition of ketamine to morphine in patient-controlled analgesia
devices (Assouline et al., 2016). The contradictory results could
be partly due to the fact that themeta-analyses did not distinguish
between different types of surgery.
The aim of this systematic review and meta-analysis was
to evaluate the influence of perioperative ketamine within a
multimodal analgesia regimen in adults undergoing surgery,
distinguishing between minor and major procedures and
excluding studies of NMDA antagonists other than ketamine to
minimize confounding and heterogeneity.
MATERIALS AND METHODS
We performed a systematic review of the literature in accordance
with the PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) statement.
Eligibility Criteria
An initial database search was undertaken to identify RCTs
examining the use of perioperative low-dose ketamine in
remifentanil-based general anesthesia for major or minor
surgery. Only studies that were performed in adults and
used morphine as a postoperative analgesic were eligible for
inclusion. RCTs reporting on postoperative cumulativemorphine
consumption, pain intensity, pain outcomes, and adverse opioid
or ketamine effects were considered.
TABLE 1 | Search strategies and results in each bibliographic database.
Database Search Query Results
PubMed ((“Remifentanil” [Supplementary Concept]) AND
“Ketamine”[Mesh]) AND “Hyperalgesia”[Mesh]
19
Cochrane Remifentanil AND Ketamine AND Hyperalgesia
Refined by: Document Types: Trials
36
Web of science TS=(Remifentanil AND Ketamine AND
Hyperalgesia)
Refined by: Databases: Core Collection AND
Document Types: Clinical Trials
57
Scopus TITLE-ABS-KEY (Remifentanil AND Ketamine
AND Hyperalgesia)
Refined by: Document Types: Articles
58
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TABLE 2 | Details of the selected studies.














NO Propofol Morphine PCA
Ganne et al. 2005 30/31 0.15 mg/kg iv +
2 µg/kg/min
0.25 µg/kg/min ENT surgery NO Propofol Morphine PCA+










NO Desfluorane Morphine PCA





Yes Sevofluorane Morphine PCA
Hadi et al. 2010 15/15 1 µg/kg/min 0.2 µg/kg/min Spinal fusion YES Sevofluorane Morphine Pump




NO Propofol Morphine PCA






NO Desfluorane Morphine PCA
Leal et al. 2015 28/28 5 µg/kg/min 0.4 µg/kg/min Laparoscopic
cholecystectomy
NO Isoflourane Morphine PCA




NO Sevofluorane Morphine PCA
Sahin et al. 2004 17/16 0.5 mg/kg iv 0.1 µg/kg/min Lumbar disk
operation
YES Desfluorane Morphine PCA
Van Elstraete 2004 20/20 0.5 mg/kg iv +
2 µg/kg/min
0.25 µg/kg/min Tonsillectomy NO Propofol Morphine i.v.
Yalcin et al. 2012 30/30 0.5 mg/kg 0.4 µg/kg/min Total
abdominal
hysterectomy
NO Desfluorane Morphine PCA
Information Sources and Search
A search of the PubMed, Web of Science, Scopus, and Cochrane
databases was performed in June 2017. Only articles written in
English or Spanish were included. The search queries used for
each database are shown in Table 1.
Study Selection
Two reviewers (JFGH and JAMM) independently performed the
search and assessed the suitability of the articles for inclusion.
In the event of disagreement, the reviewers discussed the
discrepancies and decided whether or not to include the article.
If they were unable to reach an agreement, a third reviewer
(AS) was involved. In a pre-selection phase, the abstracts of all
the articles retrieved by the literature search were screened for
eligibility. Potentially eligible studies were then assessed in depth
by examining the full text prior to inclusion.
Data Collection Process
Relevant data from selected articles were extracted and recorded
in a purpose-designed spreadsheet by a single author (JFGH)
using a standardized procedure. The authors of one original
article that met the inclusion criteria but had some missing
information on means and standard deviation were contacted
twice by e-mail, but they did not reply (Hong et al., 2011). The
information extracted by JFGH was independently reviewed by
two authors (JAMM and AS).
Data Items
The following data were extracted from each study: study
design, study population, ketamine and remifentanil
regimens, description of the intervention or control and
experimental groups, type of surgical procedure, postoperative
analgesia strategies, follow-up period, and outcome measures
(Table 2).
Primary endpoints were cumulative morphine consumption
(mg) in the first 24 h and pain intensity at 0, 2, 4, 12, and 24 h.
Pain intensity was statistically standardized on a 0–10 cm visual
analog scale (VAS). Due to the small number and heterogeneous
nature of the articles selected, there were only two secondary
endpoints: time to the first rescue analgesia and presence of
ketamine or opioid adverse effects. Patient satisfaction and
psychotic adverse effects in minor surgery were excluded from
the meta-analysis as we were unable to obtain the missing data
from the authors.
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Risk of Bias
The methodological quality of the RCTs was analyzed using
the PEDro (Maher et al., 2003) and Jadad (Clark et al., 1999)
scales. The PEDro scale is an 11-item scale that assesses (i)
notification of selection criteria, (ii) allocation of subjects to
groups at random, (iii) concealment of allocation, (iv) similarity
among groups at baseline in relation to the most important
prognostic indicators, (v) blinding of participants, (vi) blinding
of researchers/therapists, (vii) blinding of researchers measuring
at least one key outcome, (viii) proportion of initial participants
that contribute measures to the key results, (ix) compliance of
the intervention assigned by the participants, (x) presentation of
statistical comparisons between the groups, and (xi) presentation
of specific measures and variability of the key results. One
point is assigned to each criterion, except for (i), which is
not included in the final score. The total possible score thus
ranges from 0 to 10. Scores of 9 to 10 indicate excellent
quality, 6to 8 good quality, 4 to 5 fair quality, and <4 poor
quality (Gordt et al., 2018). With the Jadad scale, studies
receive a score of 0–5 points (with higher scores representing
higher methodological quality) depending on whether they (i)
are described as randomized or doubled blind, (ii) use an
appropriate randomization sequence or blinding procedure, and
(iii) provide detailed information on withdrawals and dropouts.
As studies of low methodological quality may overestimate
treatment benefits (Moher et al., 1998), we only included studies
with a PEDro score of 6 or higher (Clark et al., 1999) and
a Jadad score of 3 or higher (Kang et al., 2018; Annex 1 in
Supplementary Material).
Statistical Analysis
The 12 RCTs were grouped into 16 subgroups according to effect
size and type of surgery (major orminor) (Table 3). A study could
belong to more than one group if it reported more than one
effect size or it analyzed both major and minor surgery. Studies
could also appear more than once in the same subgroup if they
performed comparisons with different groups under the same
conditions.
The effect sizes considered were pain intensity measured on
a 10-point VAS, where 0 indicated no pain and 10 indicated
the worst possible pain; morphine consumption (mg); time to
first rescue with analgesia (minutes); incidence of postoperative
nausea and vomiting (PONV); and incidence of ketamine-related
adverse events. All the RCTs compared the administration of
ketamine and morphine (intervention group) vs. morphine only
(control group).
A meta-analysis was carried out in each subgroup to
compare the effect size between the intervention and
control group. Standardized mean differences (SMDs) and
95% confidence intervals (CIs) were used for continuous
variables (VAS, morphine consumption, and time to first
rescue analgesia), while relative risk (RR) and 95% CIs
were used for the incidence of PONV and psychotic events
(anxiety, visual disturbances, impairment of cognitive
functioning or florid psychotics symptoms like delirium
or hallucinations). The significance level was set at
p < 0.05.
Heterogeneity was determined using the Dersimonian and
Laird test and the Cochran Q statistic. A fixed-effects model was
used for studies with homogeneity and a random-effects model
was used when there was significant heterogeneity. The latter
accounts for variability due to differences between studies. The
results of the meta-analyses are shown in forest plots. The plots
show the differences between the intervention and control groups
for mean values, and RRs, showing overall measures, together
with the corresponding confidence intervals. Publication bias was
analyzed (only in subgroups with three or more studies) using
the Begg test (Z statistic) and the Egger test (t statistic). Finally,
a sensitivity analysis was carried out to study the contribution
of each study to the overall effect estimate. The analyses were




The preliminary search identified 170 articles including 15 RCTs
potentially responding to the inclusion criteria (Figure 1). Two
of the RCTs were excluded because morphine was not used for
postoperative analgesia (Launo et al., 2004; Choi et al., 2015)
and one was excluded because the manuscript was written in
Chinese (Launo et al., 2004). Twelve RCTs involving 569 adults
were therefore included in the systematic review.
The effects of ketamine and remifentanil-induced
hyperalgesia have been analyzed in two relatively recent
meta-analyses: one by Liu et al. (2012) in 2012 and another
by Wu et al. (2015) in 2015. Compared with Liu et al. (2012),
we studied five additional RCTs and excluded seven (Liu et al.,
2012), while compared with Wu et al. (2015), we studied
four additional RCTs and excluded six (Wu et al., 2015). The
studies were excluded because they included children, NMDA
receptor antagonists other than ketamine (magnesium sulfate
and amantadine), or postoperative opioids other than morphine.
Study Characteristics
The 12 RCTs were published between 2002 and 2015 (Table 2)
and had been conducted in six countries: France (Moher et al.,
1998; Clark et al., 1999; Maher et al., 2003; Launo et al., 2004;
Ganne et al., 2005; Joly et al., 2005; Yu et al., 2005; Choi et al.,
2015; Gordt et al., 2018; Kang et al., 2018), Austria (Jaksch et al.,
2002), Jordan (Hadi et al., 2010, 2013), Brazil (Leal et al., 2015),
Korea (Lee et al., 2014), and Turkey (Sahin et al., 2004; Yalcin
et al., 2012). Nine RCTs involving 413 patients were assigned
to the major surgery group while three involving 156 patients
were assigned to the minor surgery group. Although all 12 RCTs
used morphine to control postoperative pain, the administration
regimens varied. Eight studies administered morphine via a
patient-controlled analgesia system (Schmid et al., 1999; Jaksch
et al., 2002; Sahin et al., 2004; Joly et al., 2005; Hadi et al., 2010,
2013; Kim et al., 2014; Lee et al., 2014; Roeckel et al., 2016; one of
these also used paracetamol, Ganne et al., 2005) and two did not
specify the type of pump (Reddi, 2016) or infusion system used
(Van Elstraete et al., 2004).
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TABLE 3 | Characteristics of subgroups included in the meta-analysis.
Subgroup Trials included Effect size Heterogeneity test Model Publication bias*
1 Van Elstraete et al., −30min
2004
Leal et al., −30min 2015
Van Elstraete et al., −1 h 2004
Leal et al., −1 h 2015
Van Elstraete et al., −2 h 2004




Q = 225.2737; df = 5; p < 0.001
Random effects No bias
Z = 1.5029; p = 0.1329
T = −1.3473; p = 0.2492
2 Assouline et al., −1 h (2002)
Jaksch et al., −2 h (2002)




Q = 1.1184; df = 2; p = 0.5717
Fixed effects No bias
Z < 0.001; p > 0.999
T = 1.2596; p = 0.4272
3 Van Elstraete et al., 2004




Q = 14.7884; df = 1; p = 0.001
Random effects –
4 Joly et al., 2005
Ganne et al., 2005




Q = 21.5624; df = 2; p < 0.001
Random effects No bias
Z < 0.001; p > 0.999
T = −0.6603; p = 0.6285
5 Van Elstraete, 2004
Hadi et al., 2013
Hadi et al., 2013




Q = 104.3763; df = 3; p < 0.001
Random effects Bias
Z = 1.6984; p = 0.0894
T = −7.5979; p = 0.0169
6 Joly et al., 2005
Ganne et al., 2005




Q = 81.4968; df = 2; p < 0.001
Random effects No bias
Z = 1.0445; p = 0.2963
T = 2.0911; p = 0.2840
7 Van Elstraete, 2004
Hadi et al., 2013
Hadi et al., 2013




Q = 197.5201; df = 3; p < 0.001
Random effects No bias
Z = 1.6984; p = 0.0894
T = −2.1538; p = 0.1641
8 Joly et al., 2005
Ganne et al., 2005




Q = 71.2937; df = 2; p < 0.001
Random effects No bias
Z = 1.0445; p = 0.2963
T = 3.5866; p = 0.1731
9 Van Elstraete, 2004
Hadi et al., 2013
Hadi et al., 2013





Q = 118.7848; df = 3; p < 0.001
Random effects Bias
Z = 1.6984; p = 0.0894
T = −16.5343; p = 0.0036
10 Sahin et al., 2004
Ganne et al., 2005
Aubrun et al., 2008
Hadi et al., 2010
Guignard et al., 2002





Q = 326.9692; df = 5; p < 0.001
Random effects Bias
Z = 1.5029; p = 0.1329
T = −5.3088; p = 0.0061
11 Van Elstraete, 2004
Hadi et al., 2013





Q = 105.1229; df = 2; p < 0.001
Random effects Bias
Z = 1.0445; p = 0.2963
T = 419.7603; p = 0.0015
12 Jaksch et al., 2002
Guignard et al., 2002
Sahin et al., 2004





Q = 225.8723; df = 3; p < 0.001
Random effects No bias
Z = 0.3397; p = 0.7341
T = 3.6662; p = 0.0670
13 Van Elstraete, 2004
Hadi et al., 2013
Hadi et al., 2013




Q = 3.9975; df = 3; p = 0.2617
Random effects No bias
Z = −0.3397; p = 0.7341
T = −0.2830; p = 0.8038
(Continued)
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TABLE 3 | Continued
Subgroup Trials included Effect size Heterogeneity test Model Publication bias*
14 Guignard et al., 2002
Jaksch et al., 2002
Joly et al., 2005
Ganne et al., 2005




Q = 1.7537; df = 4; p = 0.7809
Fixed effects No bias
Z = 0.7348; p = 0.4624
T = 1.0131; p = 0.3856
15** Van Elstraete, 2004
Hadi et al., 2013
Hadi et al., 2013




16 Jaksch et al., 2002




Q = 0.1108; df = 1; p = 0.7393
Fixed effects –
*Results not shown for subgroups with only two studies. PONV, postoperative nausea and vomiting; VAS, visual analog scale. **Results not shown for subgroup 15, which was not
included in the meta-analysis.
FIGURE 1 | Flow diagram of the different phases of the systematic review.
Synthesis of Results
We were unable to assess the incidence of psychotic events in
minor surgery (subgroup 15) by meta-analysis because only one
of the studies yielded a result other than 0. The characteristics of
the 16 subgroups are shown in Table 3, together with the results
of the heterogeneity and publication bias tests. Subgroups 2, 14,
and 16 were homogeneous and the rest were heterogeneous. Risk
of publication bias was detected in subgroups 5, 9, 10, and 11,
and their results should, therefore, be interpreted with caution.
The results of the meta-analysis are summarized in Table 4.
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TABLE 4 | Meta-analysis results.
Subgroup Results Forest plot





40 −7.83 (−9.65; −6.0027) 16.7362
Van Elstraete, −1 h
(2004)
40 −23.5538 (−28.752218.3553) 9.3902
Van Elstraete, −2 h
(2004)
40 3.6858 (2.667; 4.7038) 18.1041
Leal, −2 h (2015) 56 0.5411 (0.0078; 1.0744) 18.6037
Leal, −30min
(2015)
56 −1.2014 (−1.7706; 0.6323) 18.5768
Leal, −1 h (2015) 56 −0.9581 (−1.5112; −0.4051) 18.5890





30 −0.4071 (−1.1302; 0.3159) 21.0181
Jaksch, −2 h
(2002)
30 −0.7381 (−1.4778; 0.0015) 20.0857
Aubrun, 0–30min
(2008)
90 −0.8615 (−1.2935; 0.4296) 58.8962
Fixed effects 150 −0.7412(−1.0727; −0.4098)
VAS 4h Minor
surgery
Van Elstraete, 2004 40 −2.1788 (−2.9612; 1.3964) 31.8379
Leal et al., 2015 56 −0.3301 (−0.8575; 0.1973) 34.5329




Joly et al., 2005 49 −1.7351 (−2.3922; 1.0781) 31.7254
Ganne et al., 2005 61 0.2193 (−0.2841; 0.7228) 33.6892
Aubrun et al., 2008 90 −0.6174 (−1.0403; 0.1945) 34.5854
Random effects 200 −0.6901 (−1.6751; 0.2948)
(Continued)
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TABLE 4 | Continued
Subgroup Results Forest plot
Study n Mean difference (95% CI) Weight (%)
VAS 12 h
Minor surgery
Van Elstraete, 2004 40 −0.6143 (−1.2485; 0.0199) 27.2404
Hadi et al., 2013 30 −12.7851 (−16.0984; −9.4719) 19.7066
Hadi et al., 2013 30 −4.9236 (−6.3604; −3.4869) 25.6965
Leal et al., 2015 56 0.5562 (0.0224; 1.0901) 27.3564
Random effects 156 −3.7999 (−6.5450; −1.0548)
VAS 12 h
Major surgery
Joly et al., 2005 49 2.3720 (1.6410; 3.1029) 32.8124
Ganne et al., 2005 61 0.5523 (0.0408; 1.0637) 33.5299
Aubrun et al., 2008 90 −1.4282 (−1.8910; −0.9653) 33.6576
Random effects 200 0.4828 (−1.5621; 2.5276)
VAS 24 h
Minor surgery
Van Elstraete, 2004 40 −2.6816 (−3.5357; −1.8275) 26.1858
Hadi et al., 2013 30 −15.8746 (−19.9546;
−11.7946)
22.5099
Hadi et al., 2013 30 −8.4976 (−10.7637–6.2315) 25.9533
Leal et al., 2015 56 2.4906 (1.7926; 3.1886) 26.2510
Random effects 156 −5.7507 (−10.8028; −0.6986)
VAS 24 h
Major surgery
Joly et al., 2005 49 2.5823 (1.8239; 3.3407) 32.6371
Ganne et al., 2005 60 0.4164 (−0.0951; 0.9279) 33.5812
Aubrun et al., 2008 90 −1.1166 (−1.5609; −0.6724) 33.7817
Random effects 199 0.6054 (−1.3021; 2.5130)
(Continued)
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TABLE 4 | Continued
Subgroup Results Forest plot




Van Elstraete, 2004 40 −1.0657 (−1.7280; −0.4033) 35.1136
Hadi et al., 2013 30 −19.3089 (−24.2468;
−14.3710)
22.1079
Hadi et al., 2013 30 −48.2743 (−60.5101;
−36.0385)
7.5228
Leal et al., 2015 56 −0.1003 (−0.6244; 0.4239) 35.2556




Sahin et al., 2004 33 1.0361 (0.3091; 1.7631) 17.3244
Ganne et al., 2005 61 0.6916 (0.1748; 1.2083) 17.4153
Aubrun et al., 2008 90 2.6299 (2.0657; 3.1942) 17.3974






Yalcin et al., 2012 53 −10.4428 (−12.5024; −8.3831) 16.1292





Van Elstraete, 2004 40 0.3305 (−0.2935; 0.9545) 34.1311
Hadi et al., 2013 30 14.6007 (10.8376; 18.3638) 32.9752
Hadi et al., 2013 30 15.1306 (11.2358; 19.0254) 32.8937






Jaksch et al., 2002 30 −1.2545 (−2.0374; −0.4716) 25.8794
Guignard et al.,
2002
50 8.85487.0329; 10.6767 25.3153
Sahin et al., 2004 33 −2.6495 (−3.5847; −1.7143) 25.823
Joly et al., 2005 49 19.9587 (15.9676; 23.9497) 22.9816
Random effects 162 5.8196 (0.2130; 11.4261)
(Continued)
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TABLE 4 | Continued
Subgroup Results Forest plot




Van Elstraete, 2004 40 1.3333 (0.3413; 5.2085) 15.8739
Hadi et al., 2013 30 0.1250 (0.0178; 0.8802) 8.4422
Hadi et al., 2013 30 0.6250 (0.2650; 1.4741) 32.0743
Leal et al., 2015 56 0.5000 (0.2564; 0.9749) 43.6096






50 0.80008 (0.2428; 2.6355) 7.0831
Jaksch et al., 2002 30 1.7500 (0.6448; 4.7497) 10.0983
Joly et al., 2005 49 1.0417 (0.4661; 2.3279) 15.5688
Ganne et al., 2005 61 1.7222 (0.4508; 6.5802) 5.6030
Aubrun et al., 2008 90 1.0000 (0.6676; 1.4980) 61.6469





Yalcin et al., 2012 30 1.0000 (0.0687; 14.553) 20.7547
Aubrun et al., 2008 90 1.6667 (0.4233; 6.5617) 79.2453
Fixed effects 120 1.4990 (0.4426; 5.0771)
PONV, Postoperative nausea and vomiting; RR, Risk ratio. Subgroup 15 was excluded from the meta-analysis.
Cumulative Morphine Consumption
Nine of the 12 RCTs reported cumulativemorphine consumption
as an outcome measure for assessing ketamine efficacy at 24 h.
The data were heterogeneous in the minor and major surgery
groups (p < 0.001). As indicated by the forest plot (Figure 1),
morphine consumption in the first 24 h was significantly lower
in the intervention group than in the control group in patients
who underwent both minor surgery (SMD = −8.3099, 95% CI:
−12.0904 to −4.5295) and major surgery (SMD = −4.0644,
95% CI: −7.0110 to −1,1178). In the case of minor surgery, the
sensitivity analysis showed that the elimination of the studies
by Van Elstraete et al. and Leal et al. would moderately change
the global effect and lead to larger CI, but it would not change
the statistical significance and the conclusions. In major surgery,
only the elimination of the study by Guignard et al. (2002)
would lead to a loss of statistical significance (Annex 2 in
Supplementary Material).
Postoperative Pain Intensity
Eight RCTs involving 475 patients reported data on pain
intensity at rest in the first 24 postoperative hours. The data
were heterogeneous at all points of follow-up except for the
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first 2 h in the minor surgery group. The forest plots showed
a significant decrease in pain intensity with ketamine and
morphine compared with morphine only in the minor surgery
group at 2, 12, and 24 h and in the major surgery group at 2 h
(Table 4). Pain intensity in the first 24 h was significantly lower
with ketamine in the minor surgery group (SMD = −5.7507,
95% CI: −10.8028 to −0.6986) but not in the major surgery
group (Table 4). According to the sensitivity analysis, removing
the studies by Van Elstraete et al. and Hadi et al. would lead
to a loss of statistical significance in some cases. On the other
hand, the elimination of the study by Ganne et al. in the case of
pain intensity after 4 h in major surgery would make the result
statistically significant, showing favorable results for the ketamine
group (Annex 2 in Supplementary Material).
Time to First Rescue Analgesia
Six RCTs involving 262 patients reported data on time of the
first request for analgesia in the postoperative period. There were
three RCTs (100 patients) in the minor surgery group and four
(162 patients) in the major surgery group, and both groups were
affected by significant heterogeneity (p < 0.001). The forest plot
shows a significantly longer time to the first rescue analgesia for
ketamine in the major surgery group (SMD = 5.8196, 95% CI:
0.2130–11.4261) but not in the minor surgery group (Table 4).
However, if the study by Van Elstraete et al. would be removed,
the results of minor surgery would be statistically significant
(Annex 2 in Supplementary Material).
Adverse Effects
Eight RCTs involving 326 patients reported on PONV, while two
involving 120 patients reported on psychotic events (Table 4).
According to the pooled analysis, ketamine administration was
not a protective or risk factor for the occurrence of adverse effects,
since all the CIs for the overall measure contained the value
RR = 1, indicating no differences between the intervention and
the control group.
DISCUSSION
Postoperative opioid-induced hyperalgesia can have significant
clinical consequences, including inadequate pain control,
increased opioid consumption, and a greater risk of adverse
effects, ultimately leading to higher morbidity, longer hospital
stays, and a greater likelihood of chronic postsurgical pain
(Fletcher and Martinez, 2014). Opioid-induced hyperalgesia
is believed to be due to changes in the central and peripheral
nervous systems that result in sensitization of the pronociceptive
pathways. Numerous mechanisms have been implicated in
the pathophysiology of this condition, notably those involving
the central glutamatergic system, since the NMDA receptor
antagonism prevents the opioid-induced pain sensitivity and the
perturbation of spinal glutamate transporter activity modulates
the development of opioid-induced hyperalgesia. The activation
of spinal dynorphin content, and the increase in the evoked
release of spinal excitatory neuropeptides such as calcitonin
gene-related peptide from primary afferents is also evoked.
Other phenomena involved are related to neuroplastic changes
in the rostral ventromedial medulla that would increase the
activity of the facilitating descending nociceptive pathways.
In addition, peripheral sensitization involving the activity
of protein kinase C is also involved (Chu et al., 2008). The
existence of multifactorial pathogenic features could explain
the conflicting results reported for the efficacy of ketamine to
date, as this anesthetic alone may not be able to block central
sensitization and prevent opioid-induced hyperalgesia (Roeckel
et al., 2016).
Low remifentanil doses (≥0.1 µg/kg/min or ≥2.7 ng/ml)
appear to be sufficient for inducing hyperalgesia (Kim et al.,
2014). We analyzed 12 RCTs comparing remifentanil-based
general anesthesia (with doses ranging from 0.01 to 0.5
µg/kg/min or 2–4 ng/ml) with and without low-dose ketamine
(infusion<1.2 mg/kg/h or bolus injection<1 mg/kg) (Kim et al.,
2014).
Our systematic review is the first to analyze the effects of
ketamine sedation according to the type of surgery (major vs.
minor). Minor surgical procedures were defined as procedures
that required a minimum hospital stay, such as arthroscopy,
laparoscopy, and microsurgery. Although greater pain intensity
might be expected after major surgery due to the size of the
surgical field, the intensity of the nociceptive stimuli, and the
longer operative times, a high incidence of postoperative pain has
also been reported for laparoscopic and other minor procedures
(Gerbershagen et al., 2013). In our study, the favorable results
observed for ketamine vs. no ketamine in the first 2, 12, and 24 h
in the minor surgery group (Table 4) may be related to the fact
that lower doses of analgesia are used for minor procedures and
they may have been insufficient to relieve postoperative pain in
the control group.
Remifentanil-based general anesthesia does not offer
sufficient guarantees for adequate postoperative pain
management in major or minor surgery without the
application of multimodal analgesic regimens adapted to
each procedure. If the necessary analgesic effect is not achieved,
activation of NMDA receptors during surgery could give
rise to an erroneous interpretation of results (Van Elstraete,
2004).
Our findings show that perioperative ketamine was associated
with a significant reduction in the consumption of morphine
24 h after minor and major surgery. Conflicting results have been
reported in the literature. In a meta-analysis of RCTs involving
649 adults and children and adults who underwent spine
surgery, Pendi et al. (2018) reported that perioperative ketamine
significantly reduced morphine consumption and pain intensity.
However, another meta-analysis of 11 studies examining the use
of ketamine in children did not find any significant reduction in
morphine consumption. The differences could be due to different
pharmacokinetic profiles in children and adults or to variations in
anesthetic regimens and pain scales (Michelet et al., 2016).
Our findings onmorphine consumption should be interpreted
with caution, as the publication bias analysis showed a risk of bias
in both the minor and major surgery subgroups. Although the
results for some of the subgroups could have been improved by
removing certain studies, we did not do this because this would
have introduced an additional source of bias and because the
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sensitivity analysis supported the robustness of the meta-analysis
results (data not shown).
Apart from exerting a morphine-sparing effect, ketamine also
significantly reduced pain intensity in the early postoperative
period after major and minor surgery, supporting results
from previous meta-analyses of NMDA receptor antagonists,
including magnesium sulfate (Liu et al., 2012; Wu et al.,
2015). The effects of remifentanil-induced hyperalgesia appear
to be greatest during this early postoperative period (Fletcher
and Martinez, 2014) and ketamine may help to reduce
pain at this time because it provides residual analgesia in
relation to its relatively rapid clearance (890–1,227 mL/min)
and short elimination half-life (2–3 h) (Mion and Villevieille,
2013).
In their meta-analysis of 14 RCTs involving 623 patients, Wu
et al. (2015) observed no differences in morphine consumption
or time to first rescue analgesia between patients who received
an NMDA receptor (ketamine or magnesium sulfate) and
controls. Conflicting findings from meta-analyses on the efficacy
of ketamine in preventing remifentanil-induced hyperalgesia
have been attributed to the inclusion of RCTs examining
several NMDA antagonists (Liu et al., 2012). In order to
avoid that, we decided to minimize sources of variability by
excluding studies of all NMDA receptor antagonists other than
ketamine. The variations observed in the anesthesia and analgesia
protocols in the RCTs included in our systematic review can be
explained by the fact that the studies were from six countries
(Table 2).
Conceptually, general anesthesia can be maintained during
surgery by total intravenous anesthesia (TIVA) or balanced
anesthesia (inhalation of volatile agents). Four of the RCTs
in our study used TIVA (with propofol) (Jaksch et al., 2002;
Van Elstraete et al., 2004; Ganne et al., 2005) while eight
used volatile agents (Schmid et al., 1999; Sahin et al., 2004;
Joly et al., 2005; Hadi et al., 2010). Propofol has traditionally
been considered to be a hypnotic sedative without analgesic
properties, although there is evidence that it might have a
modulatory effect on nociceptive processing and perception
(Bandschapp et al., 2010), reflected in the observation of less
intense postoperative pain compared with general balanced
anesthesia (Cheng et al., 2008). The potential modulatory role
of propofol in opioid-induced hyperalgesia may be due to its
interaction with GABA-A receptors at the supraspinal level
(Wang et al., 2004; Singler et al., 2007), to its non-competitive
inhibition of NMDA (in particular the NR1 subunit) (Orser et al.,
1995; Kingston et al., 2006), or to its neuroprotective effects
(demonstrated in animal models) (Grasshoff and Gillessen,
2005). Propofol could reduce hyperalgesia induced by high doses
of remifentanil during maintenance of intravenous anesthesia
(Shin et al., 2010) and consequently improve postoperative
outcomes and consumption of morphine. As shown by the
influence graph for pain intensity in the minor surgery group,
only one of the studies would have substantially modified the
overall result had it been eliminated from the meta-analysis
and this was the propofol-based anesthesia article by Van
Elstraete et al. (2004). Its removal would have eliminated
the statistical difference between the ketamine and control
groups at 30min, 1, 12, and 24 h, generating inconclusive
results.
We found no significant differences between patients who
received preemptive ketamine and those who did not for opioid-
related adverse effects or ketamine-related psychotomimetic
effects. Our findings thus support previous findings (Assouline
et al., 2016) that subanesthetic doses of perioperative ketamine
are safe.
The findings of this systematic review and meta-analysis show
that, when used as an adjuvant to morphine, ketamine reduces
postoperative morphine consumption and pain intensity in the
early postoperative period in adults undergoing major and minor
surgery. Our study has some limitations, including (1) possible
confounding by the high prevalence of postoperative pain; (2)
the variability of anesthetic regimens and study populations
together with the individual variability reflected in the different
subgroups; (3) the multifactorial pathogenesis of opioid-induced
hyperalgesia together with the lack of a protocol for the objective
measurement of different types of hyperalgesia; and (4) the lack
of standardized, clearly defined scales to measure postoperative
pain, morphine consumption, and ketamine- and opioid-related
adverse effects. These limitations should be taken into account
when designing future RCTs.
CONCLUSIONS
In summary, our systematic review and meta-analysis provide
evidence that subanesthetic intraoperative doses of ketamine
have a beneficial effect on pain control in the immediate
postoperative period (24 h), as they reduce the consumption
of postoperative morphine and the intensity of pain following
minor and major surgery. The addition of low doses of ketamine
to remifentanil-based general anesthesia regimens should be
considered.
While our findings may help to explain some of the conflicting
evidence on the use of preemptive ketamine, postoperative pain
management remains a challenge and further research using
standardized protocols and scales is needed.
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